Advances in influenza vaccination

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Reperant, Leslie A ^a,b   Rimmelzwaan, Guus F ^a   Osterhaus, Albert D M E ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Artemis One Health   (Netherlands)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; GOLD STANDARD; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N9; INFLUENZA VIRUS B; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); SEASONAL INFLUENZA; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS STRAIN;

EID: 84903182880     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-47     Document Type: Article

References (63)

1. WHO: Influenza fact sheet. [http://www.who.int/mediacentre/factsheets/ fs211/en/]
2. th Edition. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott, Williams & Wilkins; 2007: 1647-90.
3. Taubenberger JK, Kash JC: Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 2010, 7:440-51.
4. Rimmelzwaan GF, McElhaney JE: Correlates of protection: novel generations of influenza vaccines. Vaccine 2008, 26(Suppl 4): D41-4.
5. Li CK, Rappuoli R, Xu X: Correlates of protection against influenza infection in humans-on the path to a universal vaccine? Curr Opin Immunol 2013, 25:470-6.
6. Koel BF, Burke DF, Bestebroer TM, van der Vliet, Stefan, Zondag, Gerben CM, Vervaet G, Skepner E, Lewis NS, Spronken, Monique IJ, Russell CA, Eropkin MY, Hurt AC, Barr IG, de Jong, Jan C, Rimmelzwaan GF, Osterhaus, Albert DME, Fouchier, Ron AM, Smith DJ: Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013, 342:976-9.
7. Abdel-Ghafar A, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong, Menno D, Naghdaliyev A, Peiris, JS Malik, Shindo N, Soeroso S, Uyeki TM: Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008, 358:261-73.
8. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, Xiang N, Chen E, Tang F, Wang D, Meng L, Hong Z, Tu W, Cao Y, Li L, Ding F, Liu B, Wang M, Xie R, Gao R, Li X, Bai T, Zou S, He J, Hu J, Xu Y, Chai C, Wang S, Gao Y, Jin L et al.: Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China. N Engl J Med 2013.
9. Webby RJ, Webster RG: Are we ready for pandemic influenza? Science 2003, 302:1519-22.
10. Jennings LC, Monto AS, Chan, Paul KS, Szucs TD, Nicholson KG: Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008, 8:650-8.
11. Lee Y, Kim K, Ko E, Lee Y, Kim M, Kwon Y, Tang Y, Cho M, Lee Y, Kang S: New vaccines against influenza virus. Clin Exp Vaccine Res 2014, 3:12-28.
12. Corti D, Lanzavecchia A: Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013, 31:705-42.
13. Powers DC, Kilbourne ED, Johansson BE: Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol 1996, 3:511-6.
14. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Niño D, Belmont JW: Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013, 207:974-81.
15. Marcelin G, Sandbulte MR, Webby RJ: Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol 2012, 22:267-79.
16. Doyle TM, Hashem AM, Li C, van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X: Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res 2013, 100:567-74.
17. Zebedee SL, Lamb RA: Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-72.
18. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR: Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990, 64:1375-7.
19. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ: Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13:1399-402.
20. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM: Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999, 17:2237-44.
21. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-63.
22. Heinen PP, Rijsewijk FA, de Boer-Luijtze Els A, Bianchi, André TJ: Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002, 83:1851-9.
23. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L, Gerhard W: Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-26.
24. Jegerlehner A, Schmitz N, Storni T, Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-605.
25. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu T, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies M, Liao J, Emini EA, Shiver JW: Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
26. Tompkins SM, Zhao Z, Lo C, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL: Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging Infect Dis 2007, 13:426-35.
27. Fiers W, Filette M de, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X: M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-3.
28. Price GE, Soboleski MR, Lo C, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL: Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 2010, 5:e13162.
29. El Bakkouri K, Descamps F, Filette M de, Smet A, Festjens E, Birkett A, van Rooijen N, Verbeek S, Fiers W, Saelens X: Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-31.
30. Song J, van Rooijen N, Bozja J, Compans RW, Kang S: Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci USA 2011, 108:757-61.
31. Zhong W, Reed C, Blair PJ, Katz JM, Hancock K: Serum Antibody Response to Matrix Protein 2 Following Natural Infection With 2009 Pandemic Influenza A(H1N1) Virus in Humans. J Infect Dis 2014, 209:986-94.
32. Rimmelzwaan GF, Fouchier, Ron AM, Osterhaus, Albert DME: Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007, 18:529-36.
33. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A: Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013, 19:1305-12.
34. Okuno Y, Matsumoto K, Isegawa Y, Ueda S: Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 1994, 68:517-20.
35. Lipatov AS, Gitelman AK, Smirnov YuA: Prevention and treatment of lethal influenza A virus bronchopneumonia in mice by monoclonal antibody against haemagglutinin stem region. Acta Virol 1997, 41:337-40.
36. Smirnov YA, Lipatov AS, Gitelman AK, Claas EC, Osterhaus AD: Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol 2000, 145:1733-41.
37. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen L, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA: Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-73.
38. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk, Johannes P M, Skehel JJ, Lanzavecchia A: A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-6.
39. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt, Remko, Lamrani M, Korse, Hans JWM, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff, Just PJ, Vogels R, Li Olive TW, Poon, Leo LM, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen, Robert HE: Highly conserved protective epitopes on influenza B viruses. Science 2012, 337:1343-8.
40. Dilillo DJ, Tan GS, Palese P, Ravetch JV: Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 2014, 20:143-51.
41. Harris AK, Meyerson JR, Matsuoka Y, Kuybeda O, Moran A, Bliss D, Das SR, Yewdell JW, Sapiro G, Subbarao K, Subramaniam S: Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci USA 2013, 110: 4592-7.
42. Pica N, Palese P: Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
43. Chen GL, Lau Y, Lamirande EW, McCall AW, Subbarao K: Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci USA 2011, 108:1140-5.
44. Sun K, Ye J, Perez DR, Metzger DW: Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 2011, 186:987-93.
45. European Medicines Agency (EMA): Fluenz, influenza vaccine (live attenuated, nasal) EPAR summary for the public; 2011. [http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Summary-for-the-public/human/001101/ WC500103712.pdf]
46. Center of Disease Controle and Prevention (CDC): Flublok seasonal influenza (flu) vaccination. [http://www.cdc.gov/flu/protect/vaccine/qa-flublok- vaccine.htm]
47. Beyer, Walter EP, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus, Albert DME: Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013, 31:6030-3.
48. Osterholm MT, Kelley NS, Sommer A, Belongia EA: Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
49. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, García-Sastre A, Moran TM, Palese P: Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010, 107:18979-84.
50. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P: Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010, 6:e1000796.
51. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R: Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 2010, 107:13701-6.
52. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y: The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 1996, 77 (Pt 7):1483-7.
53. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P: Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, 1.
54. Weaver EA, Rubrum AM, Webby RJ, Barry MA: Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS ONE 2011, 6:e18314.
55. Chen M, Cheng TR, Huang Y, Jan J, Ma S, Yu AL, Wong C, Ho DD: A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA 2008, 105:13538-43.
56. Krammer F, Pica N, Hai R, Margine I, Palese P: Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013, 87:6542-50.
57. Wei C, Boyington JC, McTamney PM, Kong W, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang Z, Nabel GJ: Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329:1060-4.
58. Kanekiyo M, Wei C, Yassine HM, McTamney PM, Boyington JC, Whittle, James R R, Rao SS, Kong W, Wang L, Nabel GJ: Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499:102-6.
59. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A: Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29:5145-52.
60. Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK, Borisevich V, Linde JJ, Zacks MA, Li H, Kavita U, Reiserova L, Liu X, Dumuren K, Balasubramanian B, Weaver B, Parent J, Umlauf S, Liu G, Huleatt J, Tussey L, Paessler S: Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27:5875-84.
61. Ledgerwood JE, Wei C, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS: DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011, 11:916-24.
62. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais M, Duncan, Christopher JA, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill, Adrian VS, Gilbert SC: Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55:19-25.
63. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T: Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J Clin Immunol 2012, 32:595-603.